3种用药方案治疗帕金森病的成本-效果分析  

Cost-Effectiveness Analysis of 3 Therapeutic Schemes for Parkinson's Disease

作　　者：奚月芬[1] 李建[1] 

机构地区：[1]江苏省原子医学研究所附属江原医院,无锡市214063

出　　处：《中国药房》2010年第2期102-104,共3页China Pharmacy

摘　　要：目的:评价3种用药方案治疗帕金森病(PD)的成本-效果。方法:94例PD患者随机分成3组,分别给予多巴丝肼片+卡左双多巴控释片(A组)、多巴丝肼片+卡左双多巴控释片+司来吉兰片(B组)、多巴丝肼片+卡左双多巴控释片+恩他卡朋片(C组)治疗,疗程均为8周。运用药物经济学方法分析其成本-效果。结果:A、B、C组成本分别为448.78、803.89、1559.89元,有效率分别为56.67%、83.33%、85.71%,成本-效果比分别为791.92、964.71、1819.96;B、C组相对于A组的增量成本-效果比分别为1332.00、3826.14。结论:B组用药方案治疗PD较佳。OBJECTIVE ： To evaluate the cost-effectiveness of 3 therapeutic schemes in the treatment of Parkinson＇ s disease （PD）. METHODS： A total of 94 PD cases were randomly assigned into 3 groups： Group A （Benserazide tablets ＋carbidopa and Levodopa controlled release tablets）, Group B （Benserazide tablets＋Carbidopa and Levodopa controlled release tablets＋Selegiline tablets） and Group C （Benserazide tablets＋Carbidopa and Levodopa controlled release tablets＋Entacapone tablets）. After treatment for 8 weeks, the cost-effectiveness analysis were conducted for all the 3 groups. RESULTS： For Group A, B and C, the costs were 448.78, 803.89, 1 559.89 yuan, respectively; the total effective rates were 56.67%, 83.33% and 85.71%, respectively; the cost-effectiveness ratios were 791.92, 964.71,1 819.96, respectively. The incremental cost-effectiveness ratios of Group B and C were 1 332.00 and 3 826.14, respectively as against Group A. CONCLUSION： Group B is preferable for PD among the 3 groups.

关 键 词：帕金森病 治疗方案 成本-效果分析 

分 类 号：R956[医药卫生—药学] R971.5